Sudair Pharma participated in the Saudi Industry Forum 2025, reaffirming its position as a leading contributor to pharmaceutical localization, innovation, and national drug security in the Kingdom. The company used this platform to showcase its expanding capabilities in cancer drug manufacturing, insulin production, and advanced pharmaceutical technologies.
During the event, Sudair Pharma’s CEO, Dr. Yasser Alobaida, joined a distinguished panel discussion titled “Sustainability in Pharmaceutical Manufacturing: Challenges and Solutions.” His remarks highlighted the importance of technology transfer, innovation-driven production, and strategic collaborations in building a sustainable pharmaceutical ecosystem.
Dr. Alobaida shared insights into Sudair Pharma’s progress in reducing the production time and cost of essential cancer medicines, the expansion of localized insulin manufacturing, and the development of advanced biologics. These initiatives reflect the company’s commitment to supporting Saudi Arabia’s growing healthcare manufacturing sector and strengthening global competitiveness.
Parallel to the panel session, Sudair Pharma welcomed visitors to its exhibition booth, where it presented its initiatives in oncology treatments, insulin products, and next-generation pharmaceutical technologies. The booth underscored the company’s dedication to technology transfer, national talent development, and the adoption of cutting-edge manufacturing capabilities.
Sudair Pharma’s participation in the Saudi Industry Forum 2025 demonstrates its ongoing commitment to supporting Vision 2030 through innovation, localization, and sustainable growth in the pharmaceutical sector.
